Nintedanib is a small-molecule, multi-targeted tyrosine kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and specific… Read more

































Nintedanib is a small-molecule, multi-targeted tyrosine kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and specific types of non-small cell lung cancer. Laboratories rely on high-quality reference standards of Nintedanib, including its pharmacopeial and non-pharmacopeial impurities, to ensure precision in analytical testing and quality control. These materials are essential for impurity profiling, as they allow for the accurate identification and quantification of synthetic byproducts and degradation compounds. Furthermore, stable isotope labelled compounds are used as critical internal standards in mass spectrometry and bioanalytical method validation to provide precise measurement of drug concentrations in complex matrices. By incorporating these related substances into rigorous stress testing and stability studies, researchers maintain consistency and ensure adherence to global regulatory frameworks throughout the pharmaceutical development lifecycle, facilitating reliable method development and the ongoing assessment of therapeutic formulations.